| Literature DB >> 31410294 |
Hae-Ra Han1,2, Manka Nkimbeng1, Olayinka Ajomagberin1,2, Kelli Grunstra1, Phyllis Sharps1,2, Susan Renda1, Nisa Maruthur3.
Abstract
BACKGROUND: Disparities in diagnosis and control of type 2 diabetes mellitus are most evident in African Americans (AAs) with lower socioeconomic status. Health literacy is an important predictor of adequate self-management and control of diabetes. The purpose of this pilot study was to test the feasibility and preliminary efficacy of a health literacy-enhanced diabetes intervention, PLAN 4 Success (Prevention through Lifestyle intervention And Numeracy)-Diabetes, in inner-city, low-income AAs with uncontrolled type 2 diabetes.Entities:
Keywords: African American; Glucose control; Numeracy; Self-management; Type 2 diabetes
Year: 2019 PMID: 31410294 PMCID: PMC6686457 DOI: 10.1186/s40814-019-0484-8
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Main topics for each weekly education session
| Session | Content |
|---|---|
| 1 | • Types of diabetes • Risk factors for diabetes • Symptoms of diabetes • Consequences of inadequate management/treatment of diabetes • Strategies to maintain health |
| 2 | • Health screening and appointments • Communicating with healthcare providers • Management of hypo/hyperglycemia • Diabetes treatments and management |
| 3 | • Carbohydrates and blood glucose • Carb counting • Meal planning guidelines • Eating out |
| 4 | • Getting active • Exercising safely • Emotional health • Dental care |
Fig. 1Recruitment and participant tracking
Sample characteristics at baseline
| Variable | Mean (SD)a or % for the total sample ( | Mean (SD) or % for the analytical sample ( | Mean (SD) or % for the dropout sample ( |
|---|---|---|---|
| Age, years | 54.1 (8.8) | 51.5 (10.4) | 57.3 (5.6) |
| Female | 63.2 | 72.7 | 50.0 |
| < high school | 31.6 | 27.3 | 37.5 |
| Employed (full or part-time) | 26.4 | 54.6 | 25.0 |
| Difficult to manage with current household income | 36.9 | 27.3 | 50.0 |
| Insured (Medicare and/or Medicaid) | 57.9 | 63.6 | 50.0 |
| Comorbidity | 94.7 | 90.9b | 100.0c |
| On diabetes medication | 100.0 | 100.0 | 100.0 |
| Have primary physician | 89.5 | 100.0 | 75.0 |
aStandard deviation
bHypercholesterolemia (n = 7), hypertension (n = 6), heart disease (n = 2), asthma (n = 2)
cHypercholesterolemia (n = 6), hypertension (n = 6), heart disease (n = 2)
Outcome changes over 24 weeks (N = 11)
| Variable | Mean (SD) | Mean change (SD) at 12 weeksa | Mean change (SD) at 24 weeksb | Effect size at 12 weeks† | Effect size at 24 weeks†† | ||
|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | 24 weeks | |||||
| Hemoglobin A1C, % | 9.3 (1.6) | 8.9 (1.8) | 10.3 (3.2) | − 0.4 (0.8) | 0.9 (3.6) | − 0.27 | 0.58 |
| Fasting glucose, mg/dL | 195.8 (121.9) | 172.9 (52.9) | 206.4 (109.0) | − 22.9 (126.4) | 10.6 (124.1) | − 0.19 | 0.09 |
| HDL cholesterol, mg/dL | 46.5 (11.7) | 44.7 (10.3) | 44.3 (13.2) | − 1.7 (5.6) | − 2.2 (6.2) | − 0.15 | − 0.19 |
| LDL cholesterol, mg/dL | 92.5 (25.2) | 84.4 (19.4) | 83.5 (23.0) | − 8.2 (13.1) | − 9 (23.7) | − 0.33 | − 0.36 |
| Triglycerides, mg/dL | 129.1 (63.1) | 113.4 (50.0) | 141.1 (85.5) | − 15.7 (36.7) | 12 (80.2) | − 0.25 | 0.19 |
| Systolic BP, mmHg | 130.0 (13.7) | 127.5 (16.7) | 130.5 (16.9) | − 2.4 (15.1) | 0.6 (15.9) | − 0.14 | 0.04 |
| Diastolic BP, mmHg | 78.6 (7.1) | 86.3 (34.2) | 84.2 (8.3) | 7.7 (33.2) | 5.6 (7.8) | 1.09 | 0.79 |
| BMI | 40.0 (10.4) | 39.5 (9.8) | 40.8 (9.7) | − 0.6 (1.9) | − 0.3 (3.1) | − 0.06 | − 0.03 |
| LAD | 59.5 (0.9) | 58.8 (2.0) | 60 (0.0) | 0.6 (2.0) | 0.4 (0.8) | 0.69 | 0.43 |
| NVS | 1.7 (1.2) | 2.3 (1.4) | 2.4 (1.5) | 0.6 (1.4) | 0.6 (1.1) | 0.46 | 0.54 |
| PHQ-9 | 6.0 (5.7) | 7.0 (6.8) | 6.1 (6.0) | 0.6 (3.1) | − 0.6 (2.8) | 0.09 | − 0.10 |
| DKT | 6.0 (2.3) | 7.2 (1.6) | 7.5 (2.2) | 1.2 (2.3) | 1.6 (2.3) | 0.52 | 0.68 |
| DKT-insulin | 1.0 (1.2) | 1.4 (1.2) | 1.2 (1.0) | 0.4 (0.7) | 0.2 (1.2) | 0.31 | 0.15 |
| SDSES | 6.9 (1.9) | 8.0 (1.5) | 7.6 (1.8) | 1.1 (2.0) | 0.6 (2.0) | 0.57 | 0.32 |
| Self-care index | 3.8 (1.4) | 4.5 (1.4) | 3.9 (0.8) | 0.4 (1.6) | 0.2 (1.1) | 0.29 | 0.15 |
| mMOS-SS | 38.0 (12.5) | 39.1 (9.3) | 40.3 (8.7) | 1.5 (15.2) | 4.7 (16.1) | 0.12 | 0.36 |
| EQ-5 | 1.6 (0.4) | 1.6 (0.4) | 1.5 (0.4) | 0.2 (1.6) | − 0.3 (1.3) | 0.10 | − 0.14 |
| EQ-5-VAS | 62.3 (25.6) | 73.3 (23.8) | 71.4 (22.0) | 8.7 (14.5) | 13.6 (25.7) | 0.30 | 0.48 |
BMI body mass index, HDL high density lipoprotein, LDL low density lipoprotein, DKT Diabetes Knowledge Test, LAD Literacy Assessment in Diabetes, REALM Rapid Estimate of Adult Literacy, NVS Newest Vital Sign, PHQ-9 Patient Health Questionnaire-9, SDSES Stanford Diabetes Self-Efficacy scale; mMOS-SS modified Medical Outcomes Study-Social Support Survey, EQ-5 EuroQol-5, EQ-5-VAS EuroQol-5-visual analogue scale
aMean change from baseline to 12 weeks
bMean change from baseline to 24 weeks
†Mean change from baseline to 12 weeks divided by the standard deviation at baseline
††Mean change from baseline to 24 weeks divided by the standard deviation at baseline